The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The newly identified apolipoprotein AV (apoAV) gene is a key player in determining plasma triglyceride concentrations. Because hypertriglyceridemia is a major independent risk factor in coronary artery disease, the understanding of the regulation of the expression of this gene is of considerable importance. We presently characterize the structure, the transcription start site, and the promoter of the human apoAV gene. Since the peroxisome proliferator-activated receptor-alpha (PPARalpha) and the farnesoid X-activated receptor (FXR) have been shown to modulate the expression of genes involved in triglyceride metabolism, we evaluated the potential role of these nuclear receptors in the regulation of apoAV transcription. Bile acids and FXR induced the apoAV gene promoter activity. 5'-Deletion, mutagenesis, and gel shift analysis identified a heretofore unknown element at positions -103/-84 consisting of an inverted repeat of two consensus receptor-binding hexads separated by 8 nucleotides (IR8), which was required for the response to bile acid-activated FXR. The isolated IR8 element conferred FXR responsiveness on a heterologous promoter. On the other hand, in apoAV-expressing human hepatic Hep3B cells, transfection of PPARalpha specifically enhanced apoAV promoter activity. By deletion, site-directed mutagenesis, and binding analysis, a PPARalpha response element located 271 bp upstream of the transcription start site was identified. Finally, treatment with a specific PPARalpha activator led to a significant induction of apoAV mRNA expression in hepatocytes. The identification of apoAV as a PPARalpha target gene has major implications with respect to mechanisms whereby pharmacological PPARalpha agonists may exert their beneficial hypotriglyceridemic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of PPARα increases the production of lipoprotein lipase (LPL) and apolipoprotein (apo) A-V, while it decreases the plasma levels of apo C-III that inhibits LPL activity, thereby enhancing the catabolism of TG-rich lipoproteins and reducing serum TG levels [31–34].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., & Suchy, F. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011610200 · Cited by 801
Interpreting cDNA sequences: Some insights from studies on translation
Kozak, M. (1996) · Mammalian Genome · doi:10.1007/s003359900171 · Cited by 774
Jeppesen, J. Ø., Hein, H. O., Suadicani, P., & Gyntelberg, F. (1998) · Circulation · doi:10.1161/01.cir.97.11.1029 · Cited by 676
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Evidence that triglycerides are an independent coronary heart disease risk factor
Cullen, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01127-9 · Cited by 462
Assmann, G., Schulte, H., & von Eckardstein, A. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00159-2 · Cited by 447
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis
Edwards, P. A., Kast, H. R., & Anisfeld, A. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30180-2 · Cited by 385
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels
Pennacchio, L. A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3031 · Cited by 380
Rodríguez, J. C., Gil-Gómez, G., Hegardt, F. G., & Haro, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32234-2 · Cited by 378
Self-citationTalmud, P. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3039 · Cited by 365
Orphan Nuclear Receptors as eLiXiRs and FiXeRs of Sterol Metabolism
Lu, T. T., Repa, J. J., & Mangelsdorf, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100035200 · Cited by 357
Identification of a Bile Acid-responsive Element in the Human Ileal Bile Acid-binding Protein Gene
Grober, J., Zaghini, I., Fujii, H., Jones, S. A., Kliewer, S. A., Willson, T. M., Ono, T., & Besnard, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29749 · Cited by 353
van der Vliet, H. N., Sammels, M. G., Leegwater, A. C. J., Levels, J. H. M., Reitsma, P. H., Boers, W., & Chamuleau, R. A. F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106888200 · Cited by 344
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339
Kast, H. R., Nguyen, C. M., Sinal, C. J., Jones, S. A., Laffitte, B. A., Reue, K., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.10.0712 · Cited by 336
Chiang, J. Y. L., Kimmel, R., Weinberger, C., & Stroup, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10918 · Cited by 304
Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.-C., Laudet, V., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25713 · Cited by 297
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14505 · Cited by 286
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214505 · Cited by 279
Laffitte, B. A., Kast, H. R., Nguyen, C. M., Zavacki, A. M., Moore, D. D., & Edwards, P. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10638 · Cited by 275
Urizar, N. L., Dowhan, D. H., & Moore, D. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007998200 · Cited by 237
McKnight, S. L. (1982) · Cell · doi:10.1016/0092-8674(82)90129-5 · Cited by 235
Dehydroepiandrosterone Sulfotransferase Gene Induction by Bile Acid Activated Farnesoid X Receptor
Song, C. S., Echchgadda, I., Baek, B.-S., Ahn, S. C., Oh, T., Roy, A. K., & Chatterjee, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107557200 · Cited by 208
Nuclear Orphan Receptors Control Cholesterol Catabolism
Russell, D. W. (1999) · Cell · doi:10.1016/s0092-8674(00)80763-1 · Cited by 206
Miller, M., Seidler, A., Moalemi, A., & Pearson, T. A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00083-7 · Cited by 193
Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes.
Haddad, I. A., Ordovas, J. M., Fitzpatrick, T., & Karathanasis, S. K. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69300-7 · Cited by 190
Regulation of cholesterol-7α-hydroxylase: BAREly missing a SHP
Davis, R. A., Miyake, J. H., Hui, T. Y., & Spann, N. J. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31482-6 · Cited by 176
van der Vliet, H. N., Schaap, F. G., Levels, J. H. M., Ottenhoff, R., Looije, N., Wesseling, J. G., Groen, A. K., & Chamuleau, R. A. F. M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00808-2 · Cited by 168
The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese
Nabika, T., Nasreen, S., Kobayashi, S., & Masuda, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00252-6 · Cited by 134
Chawla, A., Sáez, E., & Evans, R. M. (2000) · Cell · doi:10.1016/s0092-8674(00)00097-0 · Cited by 133
Structure and expression of the human apolipoprotein A-IV gene.
Elshourbagy, N. A., Walker, D. W., Paik, Y., Boguski, M. S., Freeman, M. W., Gordon, J. I., & Taylor, J. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47513-8 · Cited by 132
Ribalta, J., Figuera, L., Fernández-Ballart, J., Vilella, E., Castro Cabezas, M., Masana, L., & Joven, J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1597 · Cited by 131
Endo, K., Yanagi, H., Araki, J., Hirano, C., Yamakawa‐Kobayashi, K., & Tomura, S. (2002) · Human Genetics · doi:10.1007/s00439-002-0825-0 · Cited by 123
Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo
Zannis, V. I., Kan, H.-Y., Kritis, A., Zanni, E. E., & Kardassis, D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00012 · Cited by 88
del Castillo-Olivares, A., & Gil, G. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.19.4035 · Cited by 87
Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter
Coste, H., & Rodrı́guez, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203421200 · Cited by 83
Self-citationIser, J. H., & Sali, A. (1981) · Drugs · doi:10.2165/00003495-198121020-00002 · Cited by 79
Effects of fenofibrate on lipid parameters in obese rhesus monkeys
Winegar, D. A., Brown, P. J., Wilkison, W. O., Lewis, M. C., Ott, R. J., Tong, W. Q., Brown, H. R., Lehmann, J. M., Kliewer, S. A., Plunket, K. D., et al. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32207-0 · Cited by 67
HDL and triglyceride as therapeutic targets
Fruchart, J., & Duriez, P. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00003 · Cited by 59
And the Answer Is, It Doesn’t Much Matter
Holmes, D. R., & Gersh, B. J. (2002) · Circulation · doi:10.1161/01.cir.0000024293.71103.3a · Cited by 41
Research works printed but not linked: 2
- Desvergne, 1999, Endocr. Rev., 20, 649
- Applied Biosystems (2001) User Bulletin 2, Foster City, CA
Cited by
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
“Secondly, PPARα agonists increase hepatic expression and plasma levels of APOA5, which is a positive regulator of LPL [220].”
BackgroundBile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“Activation of FXR induces apolipoprotein (Apo) CII and ApoA5, which are LPL activators carried by VLDL, and represses ApoCIII, which is an LPL inhibitor (Kast et al., 2001; Claudel et al., 2003; Prieur et al., 2003).”
BackgroundIntegrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
“Consistent with this finding, APOA5 mRNA is induced by PPARa activation in human and monkey hepatocytes, and APOA5 plasma levels are increased by treatment of monkeys with a synthetic PPARa agonist [173,253,254].”
BackgroundPhysiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
“There is compelling data that stimulation of LPL-mediated plasma TG clearance by fibrates may be mediated by upregulation of APOA5, which has been shown to be a direct PPARα target gene in humans but not in mice [40–42].”
BackgroundRegulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms
Chiang, J. Y. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.006 · Cited by 546
Metadata
- Authors
- Prieur, X., Coste, H., & Rodríguez, J. C.
- Affiliations
- GlaxoSmithKline (France) (FR)
- Corresponding author
- Rodríguez, Joan C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 28
- Pages
- 25468-25480
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2032849264
- Cited by
- 194
- References
- 55
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6302 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PPARα, farnesoid X receptor, bile acids, transcriptional regulation, promoter structure, transcription start sites, hypertriglyceridemia, hepatic gene expression, PPARα agonist, hypotriglyceridemic effect, triglyceride metabolism
- MeSH terms
- Apolipoprotein A-V, Receptor, Farnesoid X-Activated, Apolipoproteins, Apolipoproteins A, Base Sequence, Cell Line, Cell Nucleus, Chromosome Mapping, DNA-Binding Proteins, Exons, Carcinoma, Hepatocellular, Humans, Introns, Luciferases, Models, Genetic, Molecular Sequence Data, Mutation, Plasmids, DNA Ligases, Promoter Regions, Genetic, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Protein Biosynthesis, Transcriptional Activation, Mutagenesis, Site-Directed, Gene Deletion, Receptors, Cytoplasmic and Nuclear, Receptors, Retinoic Acid, Dimerization, 5' Untranslated Regions, Reverse Transcriptase Polymerase Chain Reaction, Response Elements, Hepatocytes, Retinoid X Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.